Patient Package Insert
N HUMAN Novo Nordisk®
Patient Information for Novolin® N
NOVOLIN® N (NO-voe-lin)
NPH,
Human Insulin Isophane Suspension Injection
(recombinant DNA origin) 100 units/mL
The following Structured Product Label (SPL) was submitted to the FDA by Novo Nordisk for the product Novolin (NDC 0169-3004). This document serves as the official prescribing information, containing essential scientific data and clinical materials required for healthcare providers and patients.
This specific version of the label includes detailed information regarding patient package insert, otc - purpose, dosage & administration, indications & usage, otc - active ingredient, inactive ingredient, principal display panel - 10ml vial, principal display panel – 10 ml relion, and other regulatory disclosures. Use the navigation below to review specific sections of the FDA submission.
N HUMAN Novo Nordisk®
Patient Information for Novolin® N
NOVOLIN® N (NO-voe-lin)
NPH,
Human Insulin Isophane Suspension Injection
(recombinant DNA origin) 100 units/mL
Important:
Know your insulin. Do not change the type of insulin you use unless told to do so by your healthcare provider. The amount of insulin you take as well as the best time for you to take your insulin may need to change if you take a different type of insulin.
Make sure that you know the type and strength of insulin that is prescribed for you.
Read the Patient Information leaflet that comes with Novolin® N before you start taking it and each time you get a refill. There may be new information. This leaflet does not take the place of talking with your healthcare provider about your diabetes or your treatment. Make sure you know how to manage your diabetes. Ask your healthcare provider if you have any questions about managing your diabetes.
What is Novolin® N?
Novolin® N is a man-made insulin (recombinant DNA origin) NPH, Human Insulin Isophane Suspension that is structurally identical to the insulin produced by the human pancreas that is used to control high blood sugar in patients with diabetes mellitus.
Who should not use Novolin® N?
Do not take Novolin® N if:
Tell your healthcare provider:
Know the medicines you take. Keep a list of your medicines with you to show all your healthcare providers when you get a new medicine.
How should I take Novolin® N?
To mix Novolin® N, roll gently and use right away. This insulin should not be used if the liquid in the vial remains clear after the vial has been rolled gently. Only use this insulin if it appears cloudy or milky. There may be air bubbles. This is normal. If the precipitate (the white deposit at the bottom of the vial) has become lumpy or granular in appearance or has formed a deposit of solid particles on the wall of the vial, do not use it, and call Novo Nordisk at 1-800-727-6500.
Novolin® N comes in:
Read the instructions for use that come with your Novolin® N product. Talk to your healthcare provider if you have any questions. Your healthcare provider should show you how to inject Novolin® N before you start taking it. Follow your healthcare provider’s instructions to make changes to your insulin dose.
|
|
|
|
|
|
|
|
Your insulin dosage may need to change because of:
|
|
|
|
|
|
See the end of this patient information for instructions about preparing and giving the injection.
What should I avoid while using Novolin® N?
What are the possible side effects of Novolin® N?
|
|
|
|
|
|
|
|
|
|
|
Severe low blood sugar (hypoglycemia) can cause unconsciousness (passing out), seizures, and death. Know your symptoms of low blood sugar. Follow your healthcare provider’s instructions for treating low blood sugar. Talk to your healthcare provider if low blood sugar is a problem for you.
These are not all of the possible side effects from Novolin® N. Ask your healthcare provider or pharmacist for more information.
Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.
How should I store Novolin® N?
All Unopened Novolin® N:
Novolin® N in use:
Vials
General advice about Novolin® N
Novolin® N is used for the treatment of diabetes only. Medicines are sometimes prescribed for conditions that are not mentioned in the patient leaflet. Do not use Novolin® N for a condition for which it was not prescribed. Do not give Novolin® N to other people, even if they have the same symptoms you have. It may harm them.
This leaflet summarizes the most important information about Novolin® N. If you would like more information about Novolin® N or diabetes, talk with your healthcare provider. For more information, call 1-800-727-6500 or visit www.novonordisk-us.com.
Helpful information for people with diabetes is published by the American Diabetes Association, 1701 N Beauregard Street, Alexandria, VA 22311 and on www.diabetes.org.
Novolin® N ingredients include:
Date of issue: January 8, 2016
Version: 8
Novolin® and Novo Nordisk® are registered trademarks of Novo Nordisk A/S.
© 2005 - 2016 Novo Nordisk
Manufactured by:
Novo Nordisk A/S
DK-2880 Bagsvaerd, Denmark
For information about Novolin® N contact:
Novo Nordisk Inc.
800 Scudders Mill Road
Plainsboro, New Jersey 08536
PATIENT INSTRUCTIONS FOR USE
Novolin® N 10 mL vial (100 Units/mL, U-100)
Before starting, gather all of the supplies that you will need to use for preparing and giving your insulin injection.
Never re-use syringes and needles.
How should I use the Novolin N vial?
How should I mix Novolin N with Regular Human insulin?
Different insulins should be mixed only under instruction from a healthcare provider. Do not mix Novolin N with any other type of insulin besides Regular human insulin. Novolin N should be mixed only when injections with syringes are used. Insulin syringes may vary in the amount of space between the bottom line and the needle (“dead space”), so if you are mixing two types of insulin be sure to discuss any change in the model and brand of syringe you are using with your healthcare provider. Novolin N can be mixed with Regular human insulin right before use. When you are mixing Novolin N insulin with Regular human insulin, always draw the Regular human (clear) insulin into the syringe first.
* Please review the disclaimer below.